Foamix Pharmaceuticals Ltd. (FOMX)

3.49
0.03 0.85
NASDAQ : Health Technology
Prev Close 3.52
Open 3.53
Day Low/High 3.41 / 3.56
52 Wk Low/High 1.97 / 6.20
Volume 129.61K
Avg Volume 684.40K
Exchange NASDAQ
Shares Outstanding 61.00M
Market Cap 213.51M
EPS -1.70
P/E Ratio 2.91
Div & Yield N.A. (N.A)

Action Was Ugly, But Healthy

If the market gaps down in the morning, watch for the dip buyers.

Foamix Reports Financial Results For Third Quarter And Nine Months Ended September 30, 2014

Foamix Reports Financial Results For Third Quarter And Nine Months Ended September 30, 2014

Conference Call Scheduled for Monday, November 17, 2014 at 8:30am Eastern / 5:30am Pacific

Foamix Announces Two New U.S. Patents Relating To Topical Tetracycline Compositions

Foamix Announces Two New U.S. Patents Relating To Topical Tetracycline Compositions

New Patents Provide Additional Coverage for Lead Product Candidates FMX101, FMX102, and FDX104

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

Foamix Pharmaceuticals Ltd. Announces Initiation Of Phase II Trial With FDX104 In Chemotherapy Induced Rash

Foamix Pharmaceuticals Ltd. Announces Initiation Of Phase II Trial With FDX104 In Chemotherapy Induced Rash

Foam Based Topical Formulation of Doxycycline is Being Developed to Treat the Most Common Side Effect of EGFRI Anti-Cancer Agents

Foamix Pharmaceuticals (FOMX) Stock Pops After IPO Pricing

Foamix Pharmaceuticals (FOMX) Stock Pops After IPO Pricing

Shares of Foamix Pharmaceuticals (FOMX) soared in morning trading Thursday after the company announced the pricing of its IPO.

TheStreet Quant Rating: D- (Sell)